Proceedings of the National Academy of Sciences of the United States of America · 2025
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Wu, Wang Siying, Ji Shuyi, Wang Jian, Lian Shuo, Li Zhe, Jansen Robin A, Wu Wei, Niu Kongyan, Sun Zhen, Jia Qi, Zheng Jiaojiao, Zhu Huijue, Deng Xuan, Wang Liqin, Fan Zhoulong, Shi Yaoping, Lieftink Cor, Guan Ming, Beijersbergen Roderick L, Qin Wenxin, Gao Qiang, Bernards René, Jin Haojie
Аннотация
Cholangiocarcinoma (CCA) remains a lethal malignancy with limited therapeutic options. Through genome-wide CRISPR-Cas9 screening, we identified the adenosine triphosphatase (ATPase) valosin-containing protein (VCP) as a critical dependency in CCA. Compound screens revealed that the VCP inhibitor CB-5339 potently suppresses CCA proliferation in a panel of patient-derived organoids by inducing cellular senescence. It is known that senescent cells persist, and this can contribute to therapy resistance. To address this, we combined CB-5339 with senolytic agents (ABT-263 and conatumumab), which selectively eliminate senescent CCA cells, resulting in enhanced tumor suppression both in vitro and in vivo. Clinical analysis showed that VCP overexpression in CCA patients correlates with poor prognosis. Our study unveils a "one-two punch" strategy, targeting VCP-mediated senescence followed by senolytic clearance, offering a promising therapeutic approach for CCA.